Sebastian Lewandowski
- Department of Clinical Neuroscience
- Division of Neuro
- Immunotherapy – Robert Harris' research group
About me
2018 - ongoing - Team Leader at the Department of Clinical Neuroscience and Center for Molecular Medicine
2008 - 2018 - Postdoc. Ulf Eriksson group, Karolinska Institutet
2005 - PhD degree. Nencki Institute of Experimental Biology, Warsaw, Poland
1997 - MSc degree. University of Gdansk, Poland
Research
Our team studies cellular mechanisms of cerebrovascular injury mechanisms in ALS neurodegeneration to find novel clinical biomarkers and therapeutic solutions.
Publication highlight:
Månberg A. et al. Nature Medicine, April 2021
"Altered perivascular fibroblast activity precedes ALS disease onset".
Nature Medicine News and Views, April 2021
"Is presymptomatic ALS perivascular?"
Karolinska Institute Press release.
"New type of cell contributes to increased understanding of ALS"
Our web resource for cell-specific gene expression in ALS:
https://alscellatlas.org/
We look at how blood vessel dysfunction and vascular remodelling lead to
increased severity of Amyotrophic Lateral Sclerosis (ALS) and FTD using
bioinformatics, in-vivo rodent models and clinical samples. We collaborate
with the leading neurology centres in Europe and US including UZ Leuven in
Belgium, Univ. Utrecht in Holland, Ulm Univ. in Germany and UCSD in San
Diego. Our results lead to novel off-label drug applications to therapy and
biomarkers in neurodegeneration including ALS, stroke and multiple sclerosis.
We offer Master student, PhD and Postdoc positions to highly motivated and
enthusiastic researchers. For details, send an email to sebastian.lewandowski@ki.se
Teaching
2020 - ongoing - PhD course director "The Vascular Brain"
2008 - ongoing - Lecturer and group discussion leader in the Biomedicine program
2018 - ongoing - MSc student supervision
Articles
- Article: JOURNAL OF CLINICAL INVESTIGATION. 2025;135(5):e171077Protzmann J; Zeitelhofer M; Stefanitsch C; Torrente D; Adzemovic MZ; Matjunins K; Randel SJI; Lewandowski SA; Muhl L; Eriksson U; Nilsson I; Su EJ; Lawrence DA; Fredriksson L
- Article: EBIOMEDICINE. 2024;110:105470Lewandowski SA; Kular L; Jagodic M
- Journal article: CEREBRAL CIRCULATION - COGNITION AND BEHAVIOR. 2024;6:100049Månberg A; Skene N; Sanders F; Szczepinska A; Remnestål J; De Vocht J; Anink J; Vergunst-Bosch H; Rodriguez-Vieitez E; Gilthorpe J; Harris R; Aronica E; Van Damme P; Ludolph A; Veldink J; Ingre C; KTH PN; Lewandowski S
- Article: FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY. 2023;11:1169962Hipke K; Pitter B; Hruscha A; van Bebber F; Modic M; Bansal V; Lewandowski SA; Orozco D; Edbauer D; Bonn S; Haass C; Pohl U; Montanez E; Schmid B
- Article: NEUROTHERAPEUTICS. 2021;18(3):1963-1979Peters S; Kuespert S; Wirkert E; Heydn R; Jurek B; Johannesen S; Hsam O; Korte S; Ludwig FT; Mecklenburg L; Mrowetz H; Altendorfer B; Poupardin R; Petri S; Thal DR; Hermann A; Weishaupt JH; Weis J; Aksoylu IS; Lewandowski SA; Aigner L; Bruun T-H; Bogdahn U
- Journal article: NATURE MEDICINE. 2021;27(7):1308Manberg A; Skene N; Sanders F; Trusohamn M; Remnestal J; Szczepinska A; Aksoylu IS; Lonnerberg P; Ebarasi L; Wouters S; Lehmann M; Olofsson J; von Gohren Antequera I; Domaniku A; De Schaepdryver M; De Vocht J; Poesen K; Uhlen M; Anink J; Mijnsbergen C; Vergunst-Bosch H; Hubers A; Klappe U; Rodriguez-Vieitez E; Gilthorpe JD; Hedlund E; Harris RA; Aronica E; Van Damme P; Ludolph A; Veldink J; Ingre C; Nilsson P; Lewandowski SA
- Article: NATURE MEDICINE. 2021;27(4):640-646Manberg A; Skene N; Sanders F; Trusohamn M; Remnestal J; Szczepinska A; Aksoylu IS; Lonnerberg P; Ebarasi L; Wouters S; Lehmann M; Olofsson J; von Gohren Antequera I; Domaniku A; De Schaepdryver M; De Vocht J; Poesen K; Uhlen M; Anink J; Mijnsbergen C; Vergunst-Bosch H; Hubers A; Klappe U; Rodriguez-Vieitez E; Gilthorpe JD; Hedlund E; Harris RA; Aronica E; Van Damme P; Ludolph A; Veldink J; Ingre C; Nilsson P; Lewandowski SA
- Journal article: DISEASE MODELS & MECHANISMS. 2020;13(5):dmm045310Crivello M; Hogg MC; Jirstrom E; Halang L; Woods I; Rayner M; Coughlan KS; Lewandowski SA; Prehn JHM
- Article: DISEASE MODELS & MECHANISMS. 2019;12(8):dmm040238Crivello M; Hogg MC; Jirstrom E; Halang L; Wood I; Rayner M; Coughlan KS; Lewandowski SA; Prehn JHM
- Article: NEUROBIOLOGY OF DISEASE. 2018;119:26-40Nonneman A; Criem N; Lewandowski SA; Nuyts R; Thal DR; Pfrieger FW; Ravits J; Van Damme P; Zwijsen A; Van Den Bosch L; Robberecht W
- Article: NEUROPHARMACOLOGY. 2018;133:503-511Crivello M; O'Riordan SL; Woods I; Cannon S; Halang L; Coughlan KS; Hogg MC; Lewandowski SA; Prehn JHM
- Article: ACTA NEUROPATHOLOGICA. 2016;131(3):453-464Lewandowski SA; Nilsson I; Fredriksson L; Lonnerberg P; Muhl L; Zeitelhofer M; Adzemovic MZ; Nichterwitz S; Lawrence DA; Hedlund E; Eriksson U
- Journal article: EXPERIMENTAL NEUROLOGY. 2014;257:182-185Abrams MB; Nilsson I; Kjell J; Lewandowski S; Codeluppi S; Eriksson U; Olson L
- Article: PLOS ONE. 2012;7(6):e38760Abrams MB; Nilsson I; Lewandowski SA; Kjell J; Codeluppi S; Olson L; Eriksson U
- Article: CARCINOGENESIS. 2009;30(4):575-579Vedin L-L; Lewandowski SA; Parini P; Gustafsson J-A; Steffensen KR
- Article: ONCOGENE. 2008;27(7):1019-1032Williams C; Edvardsson K; Lewandowski SA; Stroem A; Gustafsson J-A
- Article: ONCOGENE. 2005;24(30):4789-4798Lewandowski SA; Thiery J; Jalil A; Leclercq G; Szczylik C; Chouaib S
- Article: INTERNATIONAL JOURNAL OF CANCER. 2004;110(6):783-787Skrzypczak M; Bieche I; Szymczak S; Tozlu S; Lewandowski S; Girault I; Radwanska K; Szczylik C; Jakowicki JA; Lidereau R; Kaczmarek L
- Article: CANCER LETTERS. 2001;164(2):143-148Giermasz A; Nowis D; Jalili A; Basak G; Marczak M; Makowski M; Czajka A; Mlynarczuk I; Hoser G; Stok T; Lewandowski S; Jakóbisiak M
All other publications
- Review: FRONTIERS IN VETERINARY SCIENCE. 2023;10:1135282Cannon AE; Zurrer WE; Zejlon C; Kulcsar Z; Lewandowski S; Piehl F; Granberg T; Ineichen BV
- Review: FRONTIERS IN NEUROLOGY. 2022;13:947347Zejlon C; Nakhostin D; Winklhofer S; Pangalu A; Kulcsar Z; Lewandowski S; Finnsson J; Piehl F; Ingre C; Granberg T; Ineichen BV
- Preprint: RESEARCH SQUARE. 2021Zejlon C; Nakhostin D; Winklhofer S; Pangalu A; Lewandowski S; Finnsson J; Piehl F; Ingre C; Granberg T; Ineichen BV
- Preprint: BIORXIV. 2021Zeitelhofer M; Stefanitsch C; Protzmann J; Torrente D; Adzemovic MZ; Lewandowski SA; Muhl L; Eriksson U; Nilsson I; Su EJ; Lawrence DA; Fredriksson L
- Conference publication: INTERNATIONAL JOURNAL OF STROKE. 2020;15(1_SUPPL):624-625Zeitelhofer M; Stefanitsch C; Adzemovic M; Sue J; Lewandowski S; Muhl L; Nilsson I; Lawrence D; Fredriksson L
- Review: PHARMACOLOGY & THERAPEUTICS. 2016;167:108-119Lewandowski SA; Fredriksson L; Lawrence DA; Eriksson U
- Book chapter: HORMONAL CARCINOGENESIS IV. 2005;p. 314-320Skrzypczak M; Zagulska-Szymczak S; Lidereau R; Bieche I; Lewandowski S; Radwanska K; Szczylik C; Vidaud M; Jakowicki JA; Kaczmarek L
- Review: FEBS LETTERS. 2002;524(1-3):1-5Lewandowski S; Kalita K; Kaczmarek L
Grants
- Karolinska Institutet1 January 2024 - 1 January 2028Brain scar formation in acute injury and chronic neurodegeneration leads to permanent lesions with dramatic consequences for individual patients and healthcare systems. Previous work has described the scar- forming contributions from glial and infiltrating immune cells. Yet, recent findings challenged this notion and showed that the lesion core is formed by a newly discovered cell type - the brain perivascular fibroblast with glial cells surrounding the injury area. Single cell RNA data suggests that fibroblasts enlarge perivascular space during injury and secrete chemokines facilitating immune cell infiltration. However, without functional interventions in-vivo we still will not understand how the fibroblasts contribute to the newly formed lesions and how they interact with the immune system. We propose to examine the role of the fibroblasts in the brain injury response by examining their contribution to vascular remodeling and immune cell infiltration in an acute model of the BBB opening (Dorian McGavern at NIH) and in ALS neurodegeneration (Sebastian Lewandowski at Karolinska Institute). We propose to deplete the brain fibroblast cells using a recombinant diphtheria toxin. We will first use this approach to examine their role in a brain injury response using an acute model of blood-brain barrier (BBB) opening with focal ultrasound developed by the host lab (Mastorakos et al. Nature 1 Neuroscience 2021) . Finally, since our previous studies showed that the brain fibroblasts are activated in early stages of ALS (Månberg et al. Nature Medicine 2021)2, we will also deplete these cells in a mouse model of ALS to examine their effect on immune infiltration and disease dynamics (see Fig. 1). Completion of the proposed project will allow us to determine how fibroblasts contribute to brain repair versus neurodegeneration. By comparing the contributions of fibroblasts to these two different outcomes, we aim to identify fibroblast programs that may lead to CNS repair therapies.
- Swedish Research Council1 January 2022 - 31 December 2024
- Swedish Brain Foundation1 January 2022 - 1 January 2024
- Molecular phenotyping of brain metabolism in asymptomatic ALS/FTD patientsKarolinska Institutet1 January 2022 - 1 January 2024
- Frick Foundation1 January 2021 - 1 January 2022